5 results match your criteria: "Myeloma Center University of Arkansas for Medical Sciences Little Rock Arkansas USA.[Affiliation]"
Article Synopsis
- * Dysgeusia was experienced by 15% of patients, while the average weight loss during treatment was around 6%, with weight loss lasting for about half of the patients even after stopping the treatment.
- * To help minimize these side effects, researchers suggest that longer intervals between doses may be beneficial, indicating a need for further studies on this approach in future clinical trials.
B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma.
EJHaem
June 2024
Department of Hematology/Oncology Myeloma Center Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences Little Rock Arkansas USA.
Article Synopsis
- - Talquetamab has been approved for treating relapsed refractory multiple myeloma, but data on patient outcomes with BCMA-based therapies after progression on talquetamab is lacking.
- - A study of 10 patients showed a median follow-up of 9.5 months and a median progression-free survival of 5.5 months after switching to BCMA therapies.
- - The study indicated that while adverse effects like cytokine release syndrome and neurotoxicity were present, using talquetamab followed by BCMA therapies is a feasible treatment option.
Long-term follow-up of multiple myeloma (MM) clinical trials are needed to assess long-term outcomes. We aimed to investigate the length of follow-up of all phase III MM clinical trials. Median follow-up duration of clinical trials of newly diagnosed MM was longer when compared to relapsed/refractory MM clinical trials (42.
View Article and Find Full Text PDFGlobal public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis.
EJHaem
August 2022
Department of General Medicine Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan.
Castleman disease (CD) is a rare lymphoproliferative disorder with multiple subtypes. Thrombocytopenia, anasarca, fever, reticulin fibrosis or renal insufficiency, and organomegaly (TAFRO) syndrome can occur in the context of CD. The study evaluated worldwide public awareness of CD and TAFRO syndrome using Google Trends data between 2015 and 2021.
View Article and Find Full Text PDFGender disparities in multiple myeloma publications.
EJHaem
August 2022
Department of Hematology and Oncology, Myeloma Center Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences Little Rock Arkansas USA.
Gender disparities exist in academia and are disproportionately affecting females. We conducted a cross-sectional study to analyze gender disparities in multiple myeloma (MM) publications. A total of 679 publications with 8898 authorships were analyzed.
View Article and Find Full Text PDF